Clinical trials in ALS: A review of the role of clinical and neurophysiological measurements

References

• Turner M. R., Parton M. J., Leigh P. N. Clinical trials in ALS: an overview. Sem Neurol 2001; 21: 167–75
   PubMed Web of Science ®Google Scholar
• Miller R. G., Munsat T. L., Swash M., Brooks B. R. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on research. J Neurol Sci 1999; 169: 2–12
   PubMed Web of Science ®Google Scholar
• Matthews J. N. S., ed. An Introduction to Randomized Clinical Trials. Arnold, London 2000
   Google Scholar
• Swash M. Early diagnosis of ALS/MND. J Neurol Sci 1998; 160((Suppl))S33–6
   PubMedGoogle Scholar
• Appel S. H., Stewart S. S., Appel V., Harati Y., Mietlowski W., Weiss W., Belendiuk G. W. A double‐blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol 1988; 45: 381–6
   PubMed Web of Science ®Google Scholar
• The Italian ALS Study Group. Branched‐chain amino acids and amyotrophic lateral sclerosis: a treatment failure?. Neurology 1993; 43: 2466–70
   PubMed Web of Science ®Google Scholar
• Parton M., Mitsumoto H., Leigh P. N. Amino acids for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Library, Issue 4. John Wiley & Sons, Ltd, ChichesterUK 2004
   Google Scholar
• Smith R. A., Melmed S., Sherman B., Frane J., Munsat T. L., Festoff B. W. Recombinant growth hormone treatment of amyotrophic lateral sclerosis. Muscle Nerve 1993; 16: 624–33
   PubMed Web of Science ®Google Scholar
• Drachman D. B., Chaudhry V., Cornblath D., Kuncl R. W., Pestronk A., Clawson L., et al. Ann Neurol 1994; 35: 142–50
   PubMed Web of Science ®Google Scholar
• Bensimon G., Lacomblez L., Meininger V., and the ALS/Riluzole study group. A controlled trial of riluzole in amyotrophic lateral sclerosis. New England Journal of Medicine 1994; 330: 585–91
   PubMed Web of Science ®Google Scholar
• Miller R. G., Mitchell J. D., Moore D. H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). (Cochrane Review). The Cochrane Library, Issue 4, 2004. John Wiley & Sons, Ltd, ChichesterUK
   Google Scholar
• Louwerse E. S., Weverling G. J., Bossuyt P. M., Meyjes F. E., de Jong J. M. Randomized, double‐blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995; 52: 559–64
   PubMed Web of Science ®Google Scholar
• Orrell R. W., Lane J. M., Ross M. A. Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). The Cochrane Library, Issue 4. John Wiley & Sons, Ltd, ChichesterUK 2004
   Google Scholar
• ALS CNTF Treatment Study Group. A double‐blind placebo‐controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996; 46: 1244–9
   PubMed Web of Science ®Google Scholar
• Bongioanni P., Reali C., Sogos V. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). The Cochrane Library, Issue 4. John Wiley & Sons, Ltd, ChichesterUK 2004
   Google Scholar
• Miller R. G., Petajan J. H., Bryan W. W., Armon C., Barohn R. J., Goodpasture J. C., , and the rhCNTF ALS ALS Study Group, et al. A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 256–60
   PubMed Web of Science ®Google Scholar
• Tandan R., Bromberg M. B., Forshew R. N., Fries T. J., Badger G. J., Carpenter J., et al. A controlled trial of amino acid therapy in amyotrophic lateral sclerosis. I. Clinical, functional, and maximum isometric torque data. Neurology 1996; 47: 1220–6
   PubMed Web of Science ®Google Scholar
• Miller R. G., Moore D., Young L. A., Armon C., Barohn R. J., Bromberg M. B., Bryan W. W., et al. Placebo‐controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group. Neurology 1996; 47: 1383–8
   PubMed Web of Science ®Google Scholar
• Lacomblez L., Bensimon G., Leigh P. N., Guillet P., Meininger V. Dose‐ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 25(347)1425–31
   Google Scholar
• Lai E. c., Felice K. J., Festoff B. W., Gawel M. J., Gelinas D. F., Kratz R., et al. and the North America ALS/IGF‐I Study Group. Effects of recombinant human insulin‐like growth factor‐I on progression of ALS. A placebo controlled study. Neurology 1997; 49: 1621–30
   PubMed Web of Science ®Google Scholar
• Mitchell J. D., Wokke J. H. J., Borasio G. D. Recombinant human insulin‐like growth factor I (rhIGF‐I) for amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). The Cochrane Library, Issue 4. John Wiley & Sons, Ltd, ChichesterUK 2004
   Google Scholar
• Lange D. J., Murphy P. L., Diamond B., Appel V., Lai E. C., Younger D. S., Appel S. H. Selegiline is ineffective in a collaborative double‐blind, placebo‐controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 1998; 55: 93–6
   PubMed Web of Science ®Google Scholar
• Borasio G. D., Robberecht W., Leigh P. N., Emile J., Guilloff R. J., Jerusalem F., et al. and the European ALS/IGF‐I Study Group. A placebo‐controlled trial of insulin‐like nerve growth factor‐1 in amyotrophic lateral sclerosis. Neurology 1998; 51: 583–6
   PubMed Web of Science ®Google Scholar
• The BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 1999; 52: 1427–33
   PubMed Web of Science ®Google Scholar
• Beghi E., Chiò A., Inghilleri M., Mazzini L., Micheli A., Mora G., et al. and the Italian Amyotrophic Lateral Sclerosis Study Group. A randomized controlled trial of recombinant interferon beta‐1a in ALS. Neurology 2000; 54: 469–74
   PubMed Web of Science ®Google Scholar
• Miller R. G., Moore D. H., Gelinas D. F., Dronsky V., Mendoza M., Barohn R. J., et al. and the Western ALS Study Group. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56: 843–8
   PubMed Web of Science ®Google Scholar
• Desnuelle C., Dib M., Garrel C., Favier A. A double‐blind, placebo‐controlled randomized clinical trial of alpha‐tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole‐tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 9–18
   PubMed Web of Science ®Google Scholar
• Groeneveld G. J., Veldink J. H., van der Tweel I., Kalmijn S., Beijer C., de Visser M., et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437–45
   PubMed Web of Science ®Google Scholar
• Cudkowicz M. E., Shefner J. M., Schoenfeld D. A., Brown RH J. r., Johnson H., Qureshi M., et al. and the Northeast ALS Consortium. A randomized, placebo‐controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 2003; 61: 456–64
   PubMed Web of Science ®Google Scholar
• Meiningier V., Bensimon G., Bradley W. G., Brooks B. R., Doillet P., Eisen A. A., et al. Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 107–17
   PubMedGoogle Scholar
• Graf M., Ecker D., Horowski R., Kramer B., Riederer P., Gerlach M., et al. on behalf of the German vitamin E/ALS study group. High dose vitamin E therapy in amyotrophic lateral sclerosis as add‐on therapy to riluzole: results of a placebo‐controlled double‐blind study. J Neural Transm 2004, published on‐line October 27
   PubMedGoogle Scholar
• Shefner J. M., Cudkowicz E., shoenfeld D., Conrad T., Taft J., Chilton M., et al. and the NEALS Consortium. A clinical trial of creatine in ALS. Neurology 2004; 63: 1656–61
   PubMed Web of Science ®Google Scholar
• de Carvalho M., Scotto M., Lopes A., Swash M. Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis. Muscle Nerve 2003; 28: 630–3
   PubMed Web of Science ®Google Scholar
• de Carvalho M., Scotto M., Lopes A., Swash M. Quantifying progression in ALS. Neurology 2005; 64: 1783–5
   PubMed Web of Science ®Google Scholar
• Survival Cedarbaum J. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5((Suppl 1))79–83
   Google Scholar
• Pinto A. C., Evangelista T., de Carvalho M., Alves M., Sales‐Luís M. L. Respiratory assistance with non‐invasive ventilation (Bipap) in MND/ALS patients: survival rate in a controlled trial. J Neurol Sci 1995; 129((Suppl))19–26
   PubMed Web of Science ®Google Scholar
• Desport J. C., Preux P. M., Truong C. T., Courat L., Vallat J. M., Couratier P. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 91–6
   PubMed Web of Science ®Google Scholar
• Munsat T. L., Andres P. L., Finison L., Conlon T., Thibodeau L. The natural history of motor neuron loss in amyotrophic lateral sclerosis. Neurology 1988; 38: 409–11
   PubMed Web of Science ®Google Scholar
• Lyall R. A., Donaldson N., Polkey M. I., Leigh P. N., Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124: 2000–13
   PubMed Web of Science ®Google Scholar
• Fitting J. W., Paillex R., Hirt L., Aebischer P., Schluep M. Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis. Ann Neurol 1999; 46: 887–93
   PubMed Web of Science ®Google Scholar
• Norris FH J. r., Calanchini P. R., Fallat R. J., Panchari S., Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology 1974; 24: 721–8
   PubMedGoogle Scholar
• Appel V., Stewart S. S., Smith G., Appel S. H. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987; 22: 328–33
   PubMed Web of Science ®Google Scholar
• Cedarbaum J. M., Stambler N. Performance of Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials. J Neurol 1997; 152((Suppl 1))S1–9
   Google Scholar
• Traynor B. J., Zhang H., Shefner J. M., Schoenfeld D., Cudkowicz M., and EALS Consortium. Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004; 63: 1933–5
   PubMed Web of Science ®Google Scholar
• Swash M. Health outcome and quality‐of‐life measurements in amyotrophic lateral sclerosis. J Neurol 1997; 244((Suppl 2))S26–9
   Google Scholar
• Miller R. G., Moore D. H. ALS trial design: expectation and reality. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5((Suppl 1))52–4
   PubMedGoogle Scholar
• Cedarbaum J. M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Nakanishi A. The ALS‐FRS: a revised ALS functional rating scale that incorporates assessments of respiratpry function. BNDF ALS Study Group (phase II/III). J Neurol Sci 1999; 169: 13–21
   PubMed Web of Science ®Google Scholar
• Swash M., de Carvalho M. The neurophysiological índex in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5((Suppl 1))10810
   Google Scholar
• de Carvalho M., Chio A., Dengler R., Hecht M., Weber M., Swash M. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler Other Motor Neuron Disord., in press
   Google Scholar
• Swash M. What does the neurologist expect from clinical neurophysiology?. Muscle Nerve 2002; 11(Suppl)S1348
   Google Scholar
• Fareed G. C., Tyler R. The use of isoprinosine in patients with amyotrophic lateral sclerosis. Neurology 1971; 21: 937–40
   PubMed Web of Science ®Google Scholar
• Olson W. H., Simons J. A., Halaas G. W. Therapeutic trial of tilorone: lack of benefit in a double‐blind, placebo‐controlled study. Neurology 1978; 28: 1293–5
   PubMed Web of Science ®Google Scholar
• Munsat T. L., Easterday C. S., Levy S., Wolff S. M., Hiatt R. Amantadine and guanidine are ineffective in ALS. Neurology 1981; 31: 1054–5
   PubMed Web of Science ®Google Scholar
• Bradley W. G. Double‐blind controlled trial of purified brain gangliosides in amyotrophic lateral sclerosis and experience with peripheral neuropathies. Adv Exp Med Biol (1984); 174: 565–73
   PubMedGoogle Scholar
• Bradley W. G., Hedlund W., Cooper C., Desousa G. J., Gabbai A., Mora J. S., et al. A double‐blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis. Neurology 1984; 34: 1079–82
   PubMed Web of Science ®Google Scholar
• Harrington H., Hallett M., Tyler H. R. Gangliosides therapy for amyotrophic lateral sclerosis: a double‐blind controlled trial. Neurology 1984; 34: 1083–5
   PubMed Web of Science ®Google Scholar
• Hallett M., Harrington H., Tyler H. R., Flood T., Slater N. Trials of gangliosides for amyotrophic lateral sclerosis and diabetic neuropathy. Adv Exp Med Biol 1984; 174: 575–9
   PubMedGoogle Scholar
• Imoto K., Saida K., Iwamura K., Saida T., Nishitani H. Amyotrophic lateral sclerosis: a double‐blind crossover trial of thyrotropin‐releasing hormone. J Neurol Neurosurg Psychiatry 1984; 47: 1332–4
   PubMed Web of Science ®Google Scholar
• Olarte M. R., Shafer S. Q. Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis. Neurology 1985; 35: 1063–6
   PubMed Web of Science ®Google Scholar
• Mitsumoto H., Salgado E. D., Negroski D., Hanson M. R., Salanga V. D., Wilber J. F., et al. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin‐releasing hormone in controlled trials. Neurology 1986; 36: 152–9
   PubMedGoogle Scholar
• Brooke M. H., Florence J. M., Heller S. L., Kaiser K. K., Phillips D., Gruber A., et al. Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis. Neurology 1986; 36: 146–51
   PubMed Web of Science ®Google Scholar
• Caroscio J. T., Cohen J. A., Zawodniak J., Takai V., Shapiro A., Blaustein S., et al. A double‐blind, placebo‐controlled trial of TRH in amyotrophic lateral sclerosis. Neurology 1986; 36: 141–5
   PubMed Web of Science ®Google Scholar
• Norris F. H., Denys E. H., Fallat R. J. Trial of octaconasol in amyotrophic lateral sclerosis. Neurology 1986; 36: 1263–4
   PubMed Web of Science ®Google Scholar
• Plaitakis A., Smith J., Mandeli J., Yahr M. D. Pilot trial of branched‐chain amino acids in amyotrophic lateral sclerosis. Lancet 1988; 1: 1015–8
   PubMed Web of Science ®Google Scholar
• Lacomblez L., Bouche P., Bensimon G., Meininger V. A double‐blind, placebo‐controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology 1989; 39: 1635–7
   PubMed Web of Science ®Google Scholar
• Blin O., Serratrice G., Pouget J., Aubrespy G., Guelton C., Crevat A. Short‐term double‐blind vs. placebo trial of L‐threonine in amyotrophic lateral sclerosis. Presse Med 1989; 30: 1469–70
   Google Scholar
• Testa D., Caraceni T., Fetoni V. Branched‐chain amino acids in the treatment of amyotrophic lateral sclerosis. J. Neurol 1989; 236: 445–7
   PubMed Web of Science ®Google Scholar
• Blin O., Desnuelle C., Guelton C., Aubrespy G., Ardissonne J. P., Crevat A., et al. Anomalie des acides amines neurotransmetteurs dans la slerose lateral amyotrophique: une application therapeutique. Rev Neurol 1991; 147: 392–4
   PubMedGoogle Scholar
• Blin O., Pouget J., Aubrespy G., Guelton C., Crevat A., Serratrice G. A double‐blind placebo‐controlled trial of L‐threonine in amyotrophic lateral sclerosis. J. Neurol 1992; 239: 79–81
   PubMed Web of Science ®Google Scholar
• Gil R., Neau J. P., Courtois P., Gaucher C., Jonveaux T., Rosolacci T., et al. Essai en double aveugle contre placebo des acides amines branches et de la L‐threonine dans le traitment des signes et symptomes de la sclerose lateral amyotrophique sur un courte periode. Sem Hop Paris 1992; 68: 1472–5
   Google Scholar
• Testa D., Caraceni T., Fetoni V., Girotti. Chronic treatment with L‐threonine in amyotrophic lateral sclerosis: a pilot study. Clin Neurol Neurosurg 1992; 94: 7–9
   PubMed Web of Science ®Google Scholar
• Blin O., Pouget J., Aubrespy G., Guelton C., Crevat A., Serratrice G. A double‐blind placebo‐controlled trial of L‐threonine in amyotrophic lateral sclerosis. J Neurol 1992; 239: 79–81
   PubMed Web of Science ®Google Scholar
• Askmark H., Aquilonius S. M., Gillberg P. G., Liedholm L. J., Stalberg E., Wuopio R. A pilot trial of dextromethorphan in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 197–200
   PubMed Web of Science ®Google Scholar
• Hesselmans L. F., Wieneke G. H., Oey P. L., Groenhout D. M., van der Graaf Y., Gispen W. H., Jennekens F. G. Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease. Neuromuscul Disord 1993; 3: 319–25
   PubMedGoogle Scholar
• Eisen A., Stewart H., Schulzer M., Cameron D. Anti‐glutamate therapy in amyotrophic lateral sclerosis. Can J Neurol Sci 1993; 20: 297–301
   PubMed Web of Science ®Google Scholar
• Mazzini L., Testa D., Balzarini C., Mora G. An open.randomized clinical trial of selegiline in amyotrophic lateral sclerosis. J Neurol 1994; 241: 223–7
   PubMed Web of Science ®Google Scholar
• Jossan S. S., Ekblom J., Gudjonsson O., Hagbarth K. E., Aquilonius S. M. Double‐blind crossover trial with deprenyl in amyotrophic lateral sclerosis. J Neural Transm 1994; 41: 237–41
   Google Scholar
• Miller R. G., Shepherd R., Dao H., Khramstov A., Mendonza M., Graves J., Smith S. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromusc Disord 1996; 6: 101–4
   PubMed Web of Science ®Google Scholar
• Blin O., Azulay J. P., Desnuelle C., Bille‐Turc F., Braguer D., Besse D., et al. A controlled one‐year trial of dextromethorphan in amyotrophic lateral sclerosis. Clin Neuropharmacol 1996; 19: 189–92
   PubMed Web of Science ®Google Scholar
• Gredal O., Werdelin L., Bak S., Christensen P. B., Boysen G., Kristensen M. O., et al. A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurol Scand 1997; 96: 8–13
   PubMed Web of Science ®Google Scholar
• Kaji R., Kodama M., Imamura A., Hashida T., Kohara N., Ishizu M., et al. Effect of ultra‐high dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double‐blind controlled study. Muscle Nerve 1998; 21: 1775–8
   PubMed Web of Science ®Google Scholar
• Chio A., Cucatto A., Terreni A. A., Schiffer D. Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial. Ital J Neurol Sci 1998; 19: 363–6
   PubMedGoogle Scholar
• Bensimon G., Lacomblez L., Delumeau J. C., Bejuit R., Truffinet P., Meininger V. Riluzole/ALS Study Group. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. Journal of Neurology 2002; 249: 609–15
   PubMed Web of Science ®Google Scholar
• Ryberg H., Askmark H., Persson L. I. A double‐blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched‐chain amino acid levels and clinical parameters. Acta Neurol Scand 2003; 108: 1–8
   PubMed Web of Science ®Google Scholar
• Yuen E. C., Olney R. K. Longitudinal study of fibre density and motor unit number estimate in patients with amyotrophic lateral sclerosis. Neurology 1997; 49: 573–8
   PubMed Web of Science ®Google Scholar
• Felice K. J. A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis. Muscle Nerve 1997; 20: 179–85
   PubMed Web of Science ®Google Scholar
• Bromberg M. B., Fries T. J., Forshew D. A., Tandan R. Electrophysiological endpoint measures in a multicentre ALS drug trial. J Neurol Sci 2001; 184: 51–5
   PubMedGoogle Scholar
• Shefner J. M., Cudkowicz M. E., Zhang H., Schoenfeld D., Jillapalli D., Northeast ALS Consortium. The use of statistical MUNE in a multicentre clinical trial. Muscle Nerve 2004; 30: 463–9
   PubMed Web of Science ®Google Scholar